Cellebrite DI (NASDAQ:CLBT) Sees Large Volume Increase Following Strong Earnings

Cellebrite DI Ltd. (NASDAQ:CLBT) shares saw an uptick in trading volume on Friday following a stronger than expected earnings report. Approximately 2,477,515 shares were traded during mid-day trading, an increase of 18% from the previous session’s volume of 2,105,604 shares.The stock last traded at $10.9190 and had previously closed at $10.80.

The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.06. The company had revenue of $131.14 million for the quarter, compared to analysts’ expectations of $131.87 million. Cellebrite DI had a return on equity of 18.38% and a net margin of 14.48%.

Cellebrite DI News Roundup

Here are the key news stories impacting Cellebrite DI this week:

• Positive Sentiment: Cellebrite reported adjusted second-quarter EPS of $0.11, above the $0.05 consensus estimate cited by MarketBeat. Subscription revenue continued to grow, and management raised its adjusted EBITDA target. Cellebrite earnings and outlook announcement
• Positive Sentiment: Needham lowered its price target from $15.00 to $12.50 but maintained a Buy rating, implying potential upside from the current trading level. D.A. Davidson also retained its Buy rating. Needham analyst action
• Positive Sentiment: Unusually heavy call-option activity—nearly 20,000 contracts versus average volume of about 586—indicated that some traders were positioning for a rebound, although this is speculative and not a fundamental improvement.
• Neutral Sentiment: Cellebrite completed a planned CEO transition, appointing Shiven Ramji to succeed Thomas E. Hogan. The change could support a strategic reset, but it also introduces uncertainty during a period of lowered forecasts. CEO transition announcement
• Negative Sentiment: The key reason for the selloff was the reduced outlook. Third-quarter revenue guidance of $145 million to $148 million was below the $150.3 million consensus, while full-year revenue guidance of $555 million to $561 million trailed the $568.1 million estimate. Cellebrite also lowered its full-year ARR forecast, signaling slower near-term growth. Cellebrite outlook report
• Negative Sentiment: Quarterly revenue of $131.14 million slightly missed the $131.87 million estimate. Some data providers also characterized EPS of $0.11 as below a $0.12 consensus, reinforcing concerns that the earnings beat was less important than the revenue and ARR shortfalls.
• Negative Sentiment: Multiple law firms announced investigations into possible securities-law violations and whether prior projections and disclosures were accurate. These are allegations, not established findings, but they add legal and reputational risk. Cellebrite investigation notice
• Negative Sentiment: Former CEO Thomas Hogan sold 139,713 shares worth approximately $2.15 million, reducing his position by about 15%. The sale may be unrelated to business conditions, but its timing can weigh on investor sentiment. SEC insider sale filing

Wall Street Analyst Weigh In

A number of research firms have issued reports on CLBT. Weiss Ratings upgraded shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. Needham & Company LLC lowered their price target on shares of Cellebrite DI from $15.00 to $12.50 and set a “buy” rating on the stock in a report on Friday. Finally, DA Davidson dropped their price target on shares of Cellebrite DI from $22.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Cellebrite DI has an average rating of “Moderate Buy” and an average target price of $19.90.

Insider Transactions at Cellebrite DI

In related news, CEO Thomas E. Hogan sold 139,713 shares of Cellebrite DI stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $15.39, for a total value of $2,150,183.07. Following the completion of the sale, the chief executive officer owned 790,548 shares of the company’s stock, valued at approximately $12,166,533.72. The trade was a 15.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CRO Marcus Jewell sold 12,658 shares of the company’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $12.77, for a total transaction of $161,642.66. Following the completion of the sale, the executive owned 440,101 shares of the company’s stock, valued at $5,620,089.77. This represents a 2.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 297,934 shares of company stock worth $4,631,972 in the last 90 days. 5.70% of the stock is owned by insiders.

Institutional Trading of Cellebrite DI

Several large investors have recently made changes to their positions in CLBT. Towarzystwo Funduszy Inwestycyjnych PZU SA increased its holdings in shares of Cellebrite DI by 81.0% during the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock valued at $34,000 after acquiring an additional 850 shares during the last quarter. Advisory Services Network LLC bought a new stake in Cellebrite DI during the third quarter worth approximately $40,000. CWM LLC grew its holdings in Cellebrite DI by 57.0% during the fourth quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $44,000 after purchasing an additional 889 shares during the last quarter. Elevation Wealth Partners LLC bought a new position in shares of Cellebrite DI in the second quarter valued at approximately $44,000. Finally, First Horizon Corp lifted its stake in shares of Cellebrite DI by 421.8% in the fourth quarter. First Horizon Corp now owns 2,891 shares of the company’s stock worth $52,000 after buying an additional 2,337 shares during the last quarter. Institutional investors own 45.88% of the company’s stock.

Cellebrite DI Price Performance

The stock’s 50 day moving average price is $14.52 and its two-hundred day moving average price is $14.05. The firm has a market capitalization of $2.74 billion, a price-to-earnings ratio of 39.30, a PEG ratio of 1.89 and a beta of 1.18.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.